{"entity":{"type":"insider","cik":"0002000389","url":"/insider/0002000389","json_url":"/insider/0002000389.json","name":"Kastelein Johannes Jacob Pieter","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":10,"n_filings":5,"first":"2024-03-27","last":"2026-03-09","span_basis":"filed_date"},"name_variants":[{"name":"Kastelein Johannes Jacob Pieter","source":"filing","n_filings":5,"first_seen":"2024-03-27","last_seen":"2026-03-09"}],"transactions":[{"id":5822654,"accession":"0001193125-26-099073","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193125-26-099073","line_url":"/filing/0001193125-26-099073#line-6","is_derivative":false,"issuer_cik":"0001936258","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001936258","owner_cik":"0002000389","owner_name":"Kastelein Johannes Jacob Pieter","owner_display_name":"Kastelein Johannes Jacob Pieter","owner_url":"/insider/0002000389","role":"Director, Officer (Chief Scientific Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":101409.0,"shares_display":"101,409","price_per_share":30.29,"price_display":"30.29","price_state":"stated","total_value":3071678.61,"total_display":"3,071,678.61","total_whole":"3,071,679","shares_owned_after":69302.0,"shares_owned_after_display":"69,302","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-09","filed_date":"2026-03-09","scope":"insider"},{"id":5822651,"accession":"0001193125-26-099073","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-099073","line_url":"/filing/0001193125-26-099073#line-4","is_derivative":false,"issuer_cik":"0001936258","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001936258","owner_cik":"0002000389","owner_name":"Kastelein Johannes Jacob Pieter","owner_display_name":"Kastelein Johannes Jacob Pieter","owner_url":"/insider/0002000389","role":"Director, Officer (Chief Scientific Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":94124.0,"shares_display":"94,124","price_per_share":30.32,"price_display":"30.32","price_state":"stated","total_value":2853839.68,"total_display":"2,853,839.68","total_whole":"2,853,840","shares_owned_after":69302.0,"shares_owned_after_display":"69,302","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-06","filed_date":"2026-03-09","scope":"insider"},{"id":5822647,"accession":"0001193125-26-099073","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-099073","line_url":"/filing/0001193125-26-099073#line-2","is_derivative":false,"issuer_cik":"0001936258","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001936258","owner_cik":"0002000389","owner_name":"Kastelein Johannes Jacob Pieter","owner_display_name":"Kastelein Johannes Jacob Pieter","owner_url":"/insider/0002000389","role":"Director, Officer (Chief Scientific Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":104467.0,"shares_display":"104,467","price_per_share":30.3,"price_display":"30.30","price_state":"stated","total_value":3165350.1,"total_display":"3,165,350.10","total_whole":"3,165,350","shares_owned_after":69302.0,"shares_owned_after_display":"69,302","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-05","filed_date":"2026-03-09","scope":"insider"},{"id":6001219,"accession":"0001193125-26-067260","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-067260","line_url":"/filing/0001193125-26-067260","is_derivative":false,"issuer_cik":"0001936258","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001936258","owner_cik":"0002000389","owner_name":"Kastelein Johannes Jacob Pieter","owner_display_name":"Kastelein Johannes Jacob Pieter","owner_url":"/insider/0002000389","role":"Director, Officer (Chief Scientific Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":45481.0,"shares_display":"45,481","price_per_share":35.31140344319606,"price_display":"35.31","price_state":"stated","total_value":1605997.94,"total_display":"1,605,997.94","total_whole":"1,605,998","shares_owned_after":53500.0,"shares_owned_after_display":"53,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-20","filed_date":"2026-02-24","scope":"insider","n_lines":2},{"id":6194215,"accession":"0001193125-26-006662","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-006662","line_url":"/filing/0001193125-26-006662#line-1","is_derivative":false,"issuer_cik":"0001936258","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001936258","owner_cik":"0002000389","owner_name":"Kastelein Johannes Jacob Pieter","owner_display_name":"Kastelein Johannes Jacob Pieter","owner_url":"/insider/0002000389","role":"Director, Officer (Chief Scientific Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000.0,"shares_display":"6,000","price_per_share":33.25,"price_display":"33.25","price_state":"stated","total_value":199500.0,"total_display":"199,500.00","total_whole":"199,500","shares_owned_after":73481.0,"shares_owned_after_display":"73,481","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-05","filed_date":"2026-01-07","scope":"insider"},{"id":4133360,"accession":"0000950170-25-111241","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-111241","line_url":"/filing/0000950170-25-111241","is_derivative":false,"issuer_cik":"0001936258","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001936258","owner_cik":"0002000389","owner_name":"Kastelein Johannes Jacob Pieter","owner_display_name":"Kastelein Johannes Jacob Pieter","owner_url":"/insider/0002000389","role":"Director, Officer (Chief Scientific Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":25.1427956,"price_display":"25.14","price_state":"stated","total_value":1257139.78,"total_display":"1,257,139.78","total_whole":"1,257,140","shares_owned_after":76960.0,"shares_owned_after_display":"76,960","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-22","filed_date":"2025-08-25","scope":"insider","n_lines":2},{"id":4133350,"accession":"0000950170-25-111241","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-111241","line_url":"/filing/0000950170-25-111241#line-1","is_derivative":false,"issuer_cik":"0001936258","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001936258","owner_cik":"0002000389","owner_name":"Kastelein Johannes Jacob Pieter","owner_display_name":"Kastelein Johannes Jacob Pieter","owner_url":"/insider/0002000389","role":"Director, Officer (Chief Scientific Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":24.29,"price_display":"24.29","price_state":"stated","total_value":1214500.0,"total_display":"1,214,500.00","total_whole":"1,214,500","shares_owned_after":119302.0,"shares_owned_after_display":"119,302","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-21","filed_date":"2025-08-25","scope":"insider"},{"id":2894156,"accession":"0000950170-24-037241","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-037241","line_url":"/filing/0000950170-24-037241#line-3","is_derivative":false,"issuer_cik":"0001936258","issuer_name":"NewAmsterdam Pharma Co N.V.","issuer_ticker":"NAMS","issuer_name_source":null,"issuer_url":"/issuer/0001936258","owner_cik":"0002000389","owner_name":"Kastelein Johannes Jacob Pieter","owner_display_name":"Kastelein Johannes Jacob Pieter","owner_url":"/insider/0002000389","role":"Director, Officer (Chief Scientific Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":190476.0,"shares_display":"190,476","price_per_share":21.5,"price_display":"21.50","price_state":"stated","total_value":4095234.0,"total_display":"4,095,234.00","total_whole":"4,095,234","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-26","filed_date":"2024-03-27","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":10,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":10,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":10},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001936258","name":"NewAmsterdam Pharma Co N.V.","url":"/issuer/0001936258","role":"Director, Officer (Chief Scientific Officer)","n_filings":5,"first_seen":"2024-03-27","last_seen":"2026-03-09"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0002000389","retrieved_at":"2026-08-25T14:21:53+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}